---
title: "11:20 ET\n			\n			\n				SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COLB, PRA, GLYC on Behalf of Shareholders"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/239164161.md"
description: "Halper Sadeh LLC is investigating Columbia Banking System, Inc. (COLB), ProAssurance Corporation (PRA), and GlycoMimetics, Inc. (GLYC) for potential violations of federal securities laws and breaches of fiduciary duties. The investigation focuses on COLB's merger with Pacific Premier Bancorp, PRA's sale to The Doctors Company, and GLYC's merger with Crescent Biopharma. The firm aims to seek increased consideration for shareholders and additional disclosures. Shareholders can contact Halper Sadeh LLC for legal rights and options without upfront fees."
datetime: "2025-05-07T15:21:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/239164161.md)
  - [en](https://longbridge.com/en/news/239164161.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/239164161.md)
generator: "portal-rs"
---

# 11:20 ET
			
			
				SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COLB, PRA, GLYC on Behalf of Shareholders

, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

**Columbia Banking System, Inc. (NASDAQ: COLB)'s** merger with Pacific Premier Bancorp, Inc. Upon closing of the proposed transaction, Columbia shareholders will own approximately 70% of Columbia's outstanding shares of common stock. **If you are a Columbia shareholder,** **click here to learn more about your rights and options.**

**ProAssurance Corporation (NYSE: PRA)'s** sale to The Doctors Company for $25.00 in cash per share. **If you are a ProAssurance shareholder, click here to learn more about your rights and options.**

**GlycoMimetics, Inc. (NASDAQ: GLYC)'s** merger with Crescent Biopharma, Inc. Upon closing of the proposed transaction, GlycoMimetics stockholders are expected to own approximately 3.1% of the combined company. **If you are a GlycoMimetics shareholder, click here to learn more about your rights and options.**

Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. **We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.**

Shareholders are encouraged to contact the firm **free of charge** to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email \[email protected\] or \[email protected\].

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:  
Halper Sadeh LLC  
Daniel Sadeh, Esq.  
Zachary Halper, Esq.  
(212) 763-0060  
\[email protected\]  
\[email protected\]  
https://www.halpersadeh.com

SOURCE Halper Sadeh LLP

### Related Stocks

- [COLB.US](https://longbridge.com/en/quote/COLB.US.md)
- [GLYC.US](https://longbridge.com/en/quote/GLYC.US.md)
- [PRA.US](https://longbridge.com/en/quote/PRA.US.md)
- [CBIO.US](https://longbridge.com/en/quote/CBIO.US.md)
- [PRAA.US](https://longbridge.com/en/quote/PRAA.US.md)
- [PINC.US](https://longbridge.com/en/quote/PINC.US.md)
- [PPBI.US](https://longbridge.com/en/quote/PPBI.US.md)

## Related News & Research

- [Columbia Bank opens first commercial office, retail branch in Colorado Springs](https://longbridge.com/en/news/295272252.md)
- [Analyst Backs Crescent Biopharma With Buy Rating on Advancing ADC Pipeline and Strong Cash Runway](https://longbridge.com/en/news/294417283.md)
- [Fairmount Healthcare Fund II LP acquires 853,450 Crescent Biopharma shares for $12.38 million](https://longbridge.com/en/news/293257079.md)
- [Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights | CBIO Stock News](https://longbridge.com/en/news/294358584.md)
- [Crescent Biopharma launches underwritten public offering of ordinary shares, pre-funded warrants](https://longbridge.com/en/news/292816330.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**